Refinement of an Ultraviolet Light Sanitation Device for Central Lines; Latent Dysfunctions in Device Innovation: An STS Prospective on Equity and Access

Central line-associated bloodstream infections are a critical concern in hospital settings, causing an estimated 250,000 infections annually in the U.S. and resulting in high patient mortality and financial costs. These infections are often linked to lapses in sterility during medication or fluid administration. While current prevention strategies emphasize proper insertion and hygiene protocols, these are not always feasible in high-stress environments. This project addresses this challenge by developing a UV light sanitation device that irradiates fluids before they enter a patient’s bloodstream, minimizing intraluminal contamination without disrupting clinical workflows. Building on prior research demonstrating a 4-log reduction in S. aureus and E. coli following UV exposure and design of an initial prototype, this work focused on decreasing the prototype’s size, improving thermal management, and ensuring seamless clinical integration. The final design consists of a reusable housing containing 2 UV-C lights and a power supply, and a disposable cartridge with a Luer lock connector for seamless attachment to central lines. Iterative CAD modeling refined the layout to support optimal light exposure and fluid flow, while circuit and heat testing confirmed the device’s safety, keeping temperatures below 42°C using passive heat sinks. Although bacterial and drug compatibility testing remain ongoing due to delays, the prototype is prepared for these validations. Future steps include completing these tests, developing a scalable manufacturing process, conducting simulated clinical use evaluations, and initiating IRB-approved clinical trials. By preventing CLABSI at the point of entry, the device reduces reliance on antibiotics and limits the spread of drug- resistant bacteria, particularly S. aureus and E, without compromising the medical efficacy of medications such as insulin and epinephrine. This innovation holds strong potential to enhance patient safety, reduce healthcare costs, and provide a proactive solution to a persistent clinical challenge, ultimately contributing to broader efforts against antimicrobial resistance.